Direct-acting antiviral agents improve kidney survival in hepatitis C virus-associated cryoglobulinemia


Up to 50% of patients with hepatitis C virus (HCV) infection have elevated cryoglobulin levels, but only 2-3% develop vasculiticsymptoms of HCV-related mixed cryoglobulinemia (HCV-MC). The recently introduced direct antiviral agents (DAA) have yielded high rates of sustainable viral response in chronic HCV infection, even in chronic kidney disease patients. The RENALCRYOGLOBULINEMIC observational multicentre cohort study aimed to evaluate kidney survival and mortality in CKD patients with HCV-MC treated with DAAs. The recently published results indicate that DAA treatment significantly reduced overall mortality and improved kidney survival compared to historical controls treated with interferon and ribavirin and untreated patients.

Read more at: